Author: A. Scuteri

0000000000511426

AUTHOR

A. Scuteri

showing 6 related works from this author

Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency

2014

a b s t r a c t Background: Data on the efficacy of Peg-interferon/ribavirin therapy for chronic hepatitis C are mostly derived from treatment of selected patients enrolled in clinical trials. This study aimed to assess the effectiveness of Peg-interferon/ribavirin therapy in “real world” chronic hepatitis C patients in Italy. Methods: Independent observational multicentre study including consecutive patients receiving Peginterferon/ribavirin in the 18 months before (retrospective phase) and after (prospective phase) the start of the study. Results: 4176 patients were eligible. The final study population consisted of 2051 patients in the retrospective and 2073 in the prospective phase. Sust…

RegistrieMaleCirrhosismedicine.disease_causePolyethylene GlycolGastroenterologyPolyethylene Glycolschemistry.chemical_compoundHepatitis VirusesHepatitis ViruseProspective StudiesViralRegistriesChronicProspective cohort studyDrug CarrierDrug CarriersSettore MED/12 - GastroenterologiaMedicine (all)GastroenterologyRecombinant ProteinMiddle AgedHepatitis CRecombinant ProteinsTreatment OutcomeItalyCombinationRNA ViralPopulation studyDrug Therapy CombinationFemaleHumanmedicine.medical_specialtyGenotypeHepatitis C virusAlpha interferonRibavirin; Sustained virological response (SVR); TreatmentAntiviral AgentsFollow-Up StudieRibavirin; Sustained virological response (SVR); Treatment; Hepatology; GastroenterologyDrug TherapyInternal medicineRibavirinmedicineHumansAntiviral AgentHepatologybusiness.industryRibavirinInterferon-alphaHCV therapyHepatitis C ChronicHepatologymedicine.diseaseClinical trialTreatmentProspective StudiechemistryImmunologyRNARibavirin; Sustained virological response (SVR); Treatment; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Follow-Up Studies; Genotype; Hepatitis C Chronic; Hepatitis Viruses; Humans; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Treatment Outcome; RegistriesbusinessRibavirin; Sustained virological response (SVR); Treatment; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Follow-Up Studies; Genotype; Hepatitis C Chronic; Hepatitis Viruses; Humans; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Treatment Outcome; Registries; Gastroenterology; Hepatology; Medicine (all)Follow-Up StudiesSustained virological response (SVR)

researchProduct

Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genot…

2019

Nucleos(t)ide analogues (NAs) and peginterferon have complementary effects in chronic hepatitis B, but it is unclear whether combination therapy improves responses in genotype D-infected patients. We conducted an open-label study of peginterferon alfa-2a 180 μg/week added to ongoing NA therapy in hepatitis B e antigen (HBeAg)-negative, genotype D-infected patients with HBV DNA <20 IU/mL. The primary endpoint was proportion of patients with ≥50% decline in serum HBsAg by the end of the 48-week add-on phase. Seventy patients received treatment, 11 were withdrawn at week 24 for no decrease in HBsAg, and 14 withdrew for other reasons. Response rate (per-protocol population) was 67.4% (29/43) at…

MaleHBsAgGastroenterologyPolyethylene Glycolschronic hepatitis B; HBeAg-negative; nucleos(t)ide analogues; peginterferon; treatment; Hepatology; Infectious Diseases; Virology0302 clinical medicineInterferonGenotypeHBVHepatitis B e Antigenspeginterferonchronic hepatitis b; hbeag-negative; nucleos(t)ide analogues; peginterferon; treatment; adult; antiviral agents; drug administration schedule; drug therapy combination; female; genotype; hepatitis b e antigens; hepatitis b virus; hepatitis b chronic; humans; interferon-alpha; male; middle aged; nucleosides; polyethylene glycols; recombinant proteins; treatment outcomeeducation.field_of_studytreatmentnucleos(t)ide analoguesvirus diseasesNucleosidesMiddle AgedRecombinant ProteinsTreatment OutcomeInfectious Diseasesnucleos(t)ide analogueHBeAg030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyPeginterferon alfa-2amedicine.drugAdultHepatitis B virusmedicine.medical_specialtyGenotypeCombination therapyPopulationHBeAg-negativeInfectious DiseaseHBeAg-negative; chronic hepatitis B; nucleos(t)ide analogues; peginterferon; treatmentchronic hepatitis B; HBeAg-negative; nucleos(t)ide analogues; peginterferon; treatmentAntiviral AgentsDrug Administration Schedule03 medical and health sciencesHepatitis B ChronicInternal medicineVirologymedicineHumanschronic hepatitis BeducationHepatologybusiness.industryInterferon-alphaConfidence intervalbusiness

researchProduct

Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin

2008

Guidelines for the treatment of patients infected with hepatitis C virus of genotypes 2 and 3 (HCV-2 and HCV-3, respectively) recommend a 24-week course of Peg-interferon (Peg-IFN) alpha-2a combined with ribavirin, despite 50% of patients in registration trials attaining a sustained virologic response (SVR) following Peg-IFN alpha-2a monotherapy. The aim of this study was to delineate patient characteristics that might help to identify individuals likely to benefit from ribavirin discontinuation. One hundred and forty-four HCV-2- and HCV-3-infected patients initiated Peg-IFN alpha-2a (180 microg/week) and ribavirin (1000 or 1200 mg/day); those with viral clearance at week 4 were randomized …

AdultMalemedicine.medical_specialtyGenotypeCombination therapyHepatitis C virusHepacivirusInterferon alpha-2medicine.disease_causeChronic hepatitis CAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundVirologyInternal medicineRibavirinmedicineHumansRapid Virologic ResponseHepatologyPeg-interferonbusiness.industryRibavirinInterferon-alphavirus diseasesHepatitis CMiddle AgedViral Loadmedicine.diseaseHepatitis CRecombinant Proteinsdigestive system diseasesDiscontinuationClinical trialTreatment OutcomeInfectious DiseasesWithholding TreatmentchemistryImmunologyChronic hepatitis C; Clinical trial; Peg-interferon; Ribavirin;FemaleViral hepatitisbusinessViral load

researchProduct

Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant

2009

We assessed the efficacy and outcome of low through level of calcineurin inhibitors (CNI) and introducing mycophenolate mofetil (MMF) in liver transplant (LT) patients with CNI-related renal dysfunction. Thirty LT patients were converted to combined therapy and compared with 30 patients used as a contemporary control group receiving CNI only. The two groups were matched for sex, age, months after LT, immunosuppressive treatment, creatinine level, presence of diabetes and calculated glomerular filtration rate (GFR) via Cockroft-Gault method. After two years, in the MMF serum creatinine decreased from 1.65 mg/dL (range 1.33-3.5) to 1.4 mg/dL (range 0.9-4.7) (p = 0.002) and GFR increased from …

AdultMalemedicine.medical_specialtyUrinary systemmedicine.medical_treatmentCalcineurin InhibitorsUrologyRENAL DYSFUNCTIONRenal functionCALCINEURIN INHIBITORS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; MYCOPHENOLATE MOFETIL; RENAL DYSFUNCTIONLiver transplantationKidney Function TestsTacrolimusMycophenolic acidNephrotoxicitychemistry.chemical_compoundmedicineHumansMYCOPHENOLATE MOFETILAgedTransplantationCreatinineIMMUNOSUPPRESSIONDose-Response Relationship Drugbusiness.industryGraft SurvivalMiddle AgedMycophenolic AcidTacrolimusLiver TransplantationCalcineurinliver transplantTreatment OutcomechemistryCreatinineImmunologyKidney Failure ChronicDrug Therapy CombinationFemalebusinessImmunosuppressive AgentsGlomerular Filtration Ratemedicine.drug

researchProduct

Mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction in liver transplant: A 24-month controlled clinical trial

2007

Clinical trialCalcineurinmedicine.medical_specialtyHepatologybusiness.industryLow doseGastroenterologyUrologyMedicinebusinessMycophenolateDigestive and Liver Disease

researchProduct

Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver …

2015

In many countries, first-generation protease inhibitors (PIs)/peginterferon/ribavirin (P/R) still represent the only treatment option for HCV-infected patients. Subjects with advanced disease and previous failure to P/R urgently need therapy, but they are under-represented in clinical trials. All treatment-experienced F3/4 Metavir patients who received boceprevir (BOC)+P/R in the Italian-Spanish Name Patient Program have been included in this study. Multivariate logistic regression analysis (MLR) was used to identify baseline and on-treatment predictors of SVR and adverse events (AEs). Four hundred and sixteen patients, mean age 57.7 (range 25-78 years), 70% males, 69.5% (289/416) F4, 14% (…

researchProduct